Skip to main content

Table 3 Risk factors associated with TIC during 1 year of trastuzumab treatment

From: NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab

Independent variables Adjusted HR 95% CI P-value Patients with TICa Patients without TICa P-valueb
NT-proBNP (pmol/l)c 1.04 1.02–1.07 0.003 12 [5–19] 8 [5–12] 0.229
LVEF (%)c 1.06 0.98–1.15 0.136 64 [60–67] 60 [58–63] 0.003
Absolute LVEF decline (%) during anthracycline treatment 1.16 1.07–1.25 < 0.001 6.6 [2–9] 0.8 [−3–4] 0.033
Age (years)c 0.99 0.96–1.02 0.513 53 [47–61] 55 [47–61] 0.296
  1. Abbreviations: NT-proBNP N-terminal pro-brain natriuretic peptide, LVEF left ventricle ejection fraction, HR hazard ratio, TIC trastuzumab-induced cardiotoxicity
  2. aMedian and IQR
  3. bP-value obtained from comparison of values patients with and without TIC
  4. cMeasured at baseline